ASSOCIATION OF NON ALCOHOLIC FATTY LIVER WITH TYPE 2 DIABETES MELLITUS
Background: Non-alcoholic fatty liver disease (NAFLD) is by far the commonest cause of chronic liver disease in the developed countries. In type 2 diabetes mellitus (T2DM), NAFLD has even more aggressive course and can result in early onset chronic liver disease. Although biopsy remains the gold standard for diagnosing NAFLD, many noninvasive tests such as liver ultrasound can give a clue about the severity of the disease. This study was conducted to determine NAFLD prevalence in patients with T2DM using liver ultrasound and determine its association with the body mass index and other biochemical markers (such as liver transaminases, glycated hemoglobin HbA1c, and lipid profile).
Methods: This cross-sectional study was carried out at Azadi General Teaching Hospital from January to September 2019. All the involved patients were known to have T2DM. After being consented, their body mass index (BMI) was determined, and patients were classified into mild, moderate, and severe fatty liver based on ultrasonographic criteria. Then, the biochemical blood measurements were performed by a standard laboratory procedure to determine their lipid profile, liver transaminases, and glycated hemoglobin levels.
Results: One hundred thirty diabetic patients were involved in the study. Around 55% were overweight, and 34% were obese. Fatty liver was seen in 53.7% (74 patients). Among these, mild, moderate and severe NAFLD was seen in 79.9%, 17.7% and 4.35%, respectively. Fatty liver diabetics had a mean BMI of 32.09% vs. 27.59% for patients with non-fatty liver. The average mean HbA1c, triglyceride and GPT levels in fatty liver and non fatty liver diabetics were 8.37 % vs. 7.82 %, 200mg/dl vs. 150mg/dl and 24.4 IU/L vs. 20.4 IU/L, respectively.
Conclusion: The overall prevalence of NAFLD among type 2 diabetes mellitus patients is significantly high. Elevated GPT, triglyceride and HbA1c levels may correlate with the development of NAFLD in diabetic patients.
2. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012; 10(8):837-58.
3. White DL, Kanwal F, El-Serag HB. Association between non-alcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012; 10(12):1342-59.
4. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37(6):1286-92.
5. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140(1): 124-31.
6. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome. Diabetes. 2001; 50(8): 1844-50.
7. Forlani G, Giorda C, Manti R, Mazzella N, De Cosmo S, Rossi MC, et al. The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes. J Diabetes Res. 2016; doi: 10.1155/ 2016/2931985.
8. Jäger S, Jacobs S, Kröger J, Stefan N, Fritsche A, Weikert C, et al. Association between the fatty liver index and risk of type 2 diabetes in the EPIC-Potsdam Study. PLoS One. 2015; doi: 10.1371/ journal. pone. 0124749.
9. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016; 65(8): 1096-108.
10. Merat S, Malekzadeh R, Tahaghoghi S, Alizadeh Z, Sedighi N, Ghorbani A, et al. Prevalence of Fatty Liver Disease among Type 2 Diabetes Mellitus Patients and it Relation to Insulin Resistance. MEJDD. 2009; 1(2):74-9.
11. Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. Int. J. Mol. Sci. 2013; 14 (11): 22933-66.
12. Angulo P, Keach JC, Batts KP, Lindor KD, Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis, Hepatology. 1999; 30(6): 1356-62.
13. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough A. Nonalcoholic fatty liver disease in patients with type 2 diabetes, Clin Gastroenterol Hepatol. 2004; 2(3): 262-5.
14. Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes, Curr Diab Rep. 2007; 7(3): 175-80.
15. Kim SH, Lee JM, Kim JH, Han JK, Park SH, Sush K, et al. Appropriateness of a Donor Liver with Respect to Macrosteatosis: Application of Artificial Neural Networks to US Images--Initial Experience. Radiology. 2005; 234(3): 793-803.
16. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95.
17. Bril F, Solano F, Lomonaco R, Orsak B, Freckleton M, Chintapalli K, et al. Clinical value of liver ultrasound for the diagnosis of non-alcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015; 35(9): 2139-46.
18. Koehler EM, Plompen EP, Schouten JN, Hansen BE, Murad SD, Taimr P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population : the Rotterdam study. Hepatology. 2016; 63(1): 138-47.
19. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, et al. Noninvasive screening of diabetics in primary carefor NAFLD and advancedfibrosis by MRI andMRE. Aliment Pharmacol Ther. 2016; 43(1): 83-95
20. Portillo-Sanchez P, Bril F, Maximos M|, Lomonaco R, Biernacki D, Orsak B, et al. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. JCEM. 2015; 100(6): 2231-38.
21. Adams LA, Harmsen S, Sauver JL, Enders FB, Therneau T, Angulo P. Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients with Diabetes: A Community-Based Cohort Study. Am J Gastroenterol. 2010; 105 (7):1567-73.
22. Onyekwere CA, Ogbega AO, Balogun BO. Non-Alcoholic Fatty Liver Disease and the metabolic syndrome in an urban hospital serving an Africa community. Ann hepatol. 2011; 10(2): 119-24
23. Yi M, Chen RP, Yang R, Chen H. Increased prevalence and risk of non‐alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China. Diabet Med. 2017; 34(4): 505-13.
24. Lazo M, Clark JM. The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective: Sociodemographic Differences in the Prevalence of NAFLD. Semin Liver Dis. 2008; 28(4): 339-350.
25. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of Nonalcoholic Fatty Liver Disease and Its Association with Cardiovascular Disease among Type 2 Diabetic Patients. Diabetes Care. 2007; 30 (5): 1212-18.
26. Harris EH. Elevated Liver Function Tests in Type 2 Diabetes. Clin Diabetes 2005; 23(3): 115-19.
27. Neely D. Liver enzymes, fatty liver and type 2 diabetes. Ann Clin Biochem. 2005; 42 (3):167-9.
28. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009; 16(2): 141-9.
29. Smith D, Jessurun S, Parks B. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease. J Clin Invest. 2005; 115(5): 1343- 51.
30. Atan NA, Koushki M, Motedayen M, Dousti M, Sayehmiri F,Vafaee R, et al, Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis , Gastroenterol Hepatol Bed Bench. 2017; 10(1): 123-5.
31. Zawdie B, Tadesse S, Wolide AD, Nigatu TA, Bobasa EM. Non-Alcoholic Fatty Liver Disease and Associated Factors among Type 2 Diabetic Patients in Southwest Ethiopia, Ethiop J Health Sci. 2018; 28(5):19-27.